CatalystMarker
← board

INVA

distress 0/10 · well-funded / low risk
$21.15-1%today-13% from 52w high
inva.com159 employeesFounded 1996Burlingame, CABiotechnology
Revenue
$98M
Liquidity
$1016M
Runway
Shares 1y
+17%

Price & events

+7.1% over 6M
$19.52$21.88$24.24Jan 26Apr 26Jul 262.8Mrating: BTIG: Buy (2026-06-22)rating: HC Wainwright & Co.: Buy (2026-06-01)rating: BTIG: Buy (2026-05-26)rating: BTIG: Buy (2026-05-07)rating: BTIG: Buy (2026-02-26)rating: BTIG: Buy (2026-02-17)
CatalystRating changeDilutionFinancingdashed = today
-1.3%
1D
-4.8%
1W
-10.2%
1M
-9.9%
3M
+8.1%
6M
+9.7%
1Y
+18.7%
2Y
+58.3%
5Y
+69.5%
All

Overview

Market Cap
$1.56B
Enterprise Value
$1.22B
Volume
29.57K
52 Week Range
$16.67 – $24.24
Total Shares
73.81M
Float Shares
69.20M
Short %
12.13%
% Held by Insiders
0.99%
% Held by Institutions
107.92%
RVOL
0.04x
Beta
0.34

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 73,808,749 · 0 offerings/1y · 0 PIPEs
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $36 (+68% upside) · 4 analysts
  • 2026-06-22BTIGBuy
  • 2026-06-01HC Wainwright & Co.Buy
  • 2026-05-26BTIGBuy
  • 2026-05-07BTIGBuy
  • 2026-02-26BTIGBuy
  • 2026-02-17BTIGBuy

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.